Shots:
IntraGel Therapeutics has entered into a strategic collaboration and investment agreement with UroGen Pharma to advance TumoCure for advanced head and neck cancer and expand the potential application of its SRGel biodegradable sustained-release platform
As per the deal, UroGen will invest up to $7M in IntraGel to support the P-II development of TumoCure and…
